ambroxol has been researched along with Innate Inflammatory Response in 10 studies
Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to investigate the protective effects of ambroxol in psoriasis-like skin inflammation both in vitro and in vivo and delineate the molecular mechanism of ambroxol." | 7.91 | Protective effects of ambroxol in psoriasis like skin inflammation: Exploration of possible mechanisms. ( Challa, VS; Godugu, C; Pooladanda, V; Sunkari, S; Thatikonda, S, 2019) |
| "Ambroxol is a mucus-modifying drug with a known ability to stimulate surfactant secretion and inhibit, in vitro, the production of proinflammatory cytokines, neutrophil chemotaxis, and Na+ absorption by the airway epithelium." | 6.68 | Intraluminal inflammation in the airways of patients with chronic bronchitis after treatment with Ambroxol. ( Capelli, A; Cerutti, CG; Donner, CF; Lusuardi, M; Salmona, M; Tacconi, MT, 1995) |
| "Ambroxol's effects were compared with those of gabapentin." | 5.33 | Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. ( Arndt, K; Gaida, W; Klinder, K; Weiser, T, 2005) |
| "Ambroxol is frequently used as mucolytic agent in respiratory diseases associated with increased mucus production like acute or chronic bronchitis." | 4.84 | Antiinflammatory properties of ambroxol. ( Beeh, KM; Beier, J; Esperester, A; Paul, LD, 2008) |
| "The purpose of this study was to investigate the protective effects of ambroxol in psoriasis-like skin inflammation both in vitro and in vivo and delineate the molecular mechanism of ambroxol." | 3.91 | Protective effects of ambroxol in psoriasis like skin inflammation: Exploration of possible mechanisms. ( Challa, VS; Godugu, C; Pooladanda, V; Sunkari, S; Thatikonda, S, 2019) |
| "Ambroxol inhibited proinflammatory cytokines, reduced lung inflammation and accelerated recovery from LPS-induced ALI." | 3.72 | Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide. ( Bai, C; Song, Y; Su, X; Wang, L, 2004) |
| "Ambroxol is a mucus-modifying drug with a known ability to stimulate surfactant secretion and inhibit, in vitro, the production of proinflammatory cytokines, neutrophil chemotaxis, and Na+ absorption by the airway epithelium." | 2.68 | Intraluminal inflammation in the airways of patients with chronic bronchitis after treatment with Ambroxol. ( Capelli, A; Cerutti, CG; Donner, CF; Lusuardi, M; Salmona, M; Tacconi, MT, 1995) |
| "Ambroxol's effects were compared with those of gabapentin." | 1.33 | Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain. ( Arndt, K; Gaida, W; Klinder, K; Weiser, T, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Mitini-Nkhoma, SC | 1 |
| Fernando, N | 1 |
| Ishaka, GKD | 1 |
| Handunnetti, SM | 1 |
| Pathirana, SL | 1 |
| Maihöfner, C | 1 |
| Schneider, S | 1 |
| Bialas, P | 1 |
| Gockel, H | 1 |
| Beer, KG | 1 |
| Bartels, M | 1 |
| Kern, KU | 1 |
| Sunkari, S | 1 |
| Thatikonda, S | 1 |
| Pooladanda, V | 1 |
| Challa, VS | 1 |
| Godugu, C | 1 |
| Belkouch, M | 1 |
| Dansereau, MA | 1 |
| Tétreault, P | 1 |
| Biet, M | 1 |
| Beaudet, N | 1 |
| Dumaine, R | 1 |
| Chraibi, A | 1 |
| Mélik-Parsadaniantz, S | 1 |
| Sarret, P | 1 |
| Beeh, KM | 1 |
| Beier, J | 1 |
| Esperester, A | 1 |
| Paul, LD | 1 |
| Su, X | 1 |
| Wang, L | 1 |
| Song, Y | 1 |
| Bai, C | 1 |
| Gaida, W | 1 |
| Klinder, K | 1 |
| Arndt, K | 1 |
| Weiser, T | 1 |
| Lusuardi, M | 1 |
| Capelli, A | 1 |
| Salmona, M | 1 |
| Tacconi, MT | 1 |
| Cerutti, CG | 1 |
| Donner, CF | 1 |
| Ishibashi, Y | 1 |
| Okamura, T | 1 |
| Masumoto, Y | 1 |
| Tachiiri, T | 1 |
| Momo, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Ambroxol on the Inflammatory Markers and Clinical Outcome of Patients With Diabetic Peripheral Neuropathy[NCT05558878] | 80 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ambroxol and Innate Inflammatory Response
| Article | Year |
|---|---|
Antiinflammatory properties of ambroxol.
Topics: Administration, Oral; Ambroxol; Anti-Inflammatory Agents; Bronchitis; Humans; Inflammation; Pharyngi | 2008 |
1 trial available for ambroxol and Innate Inflammatory Response
| Article | Year |
|---|---|
Intraluminal inflammation in the airways of patients with chronic bronchitis after treatment with Ambroxol.
Topics: Ambroxol; Bronchi; Bronchitis; Bronchoalveolar Lavage Fluid; Chronic Disease; Double-Blind Method; E | 1995 |
8 other studies available for ambroxol and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Ion Transport Modulators Differentially Modulate Inflammatory Responses in THP-1-Derived Macrophages.
Topics: Ambroxol; Cells, Cultured; Humans; Immunomodulation; Inflammation; Interleukin-1beta; Ion Transport; | 2021 |
Successful treatment of complex regional pain syndrome with topical ambroxol: a case series.
Topics: Administration, Topical; Adult; Aged; Ambroxol; Anesthetics, Local; Complex Regional Pain Syndromes; | 2018 |
Protective effects of ambroxol in psoriasis like skin inflammation: Exploration of possible mechanisms.
Topics: Ambroxol; Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Humans; Hyperplasia; | 2019 |
Functional up-regulation of Nav1.8 sodium channel in Aβ afferent fibers subjected to chronic peripheral inflammation.
Topics: Ambroxol; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Freund's Adjuvant; Ganglia, Spi | 2014 |
Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide.
Topics: Ambroxol; Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Dexamethasone; Disease Mo | 2004 |
Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain.
Topics: Ambroxol; Amines; Analgesics; Animals; Behavior, Animal; Constriction, Pathologic; Cyclohexanecarbox | 2005 |
[Effects of carbocisteine on airway inflammation and related events in SO2-exposed rats].
Topics: Ambroxol; Animals; Carbocysteine; Cyclic AMP; Disease Models, Animal; Expectorants; Gases; Inflammat | 2001 |